Systemic lupus erythematosus and myelofibrosis
References (30)
- et al.
Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell
Blood
(1981) - et al.
Immune complexes in myeloproliferative disorders
Lancet
(1977) - et al.
Immunologic abnormalities in myelofibrosis with activation of the complement system
Blood
(1981) - et al.
Hematologic aspects of systemic lupus erythematosus
Ann Intern Med
(1977) Connective tissue diseases
Clin Haematol
(1972)The bone marrow in systemic lupus erythematosus
Semin Hematol
(1965)- et al.
Red-cell hypoplasia and increased bone marrow reticulin in systemic lupus erythematosus; reversal with corticosteroid therapy
Am J Hematol
(1978) - et al.
Myelosclerosis associated with systemic lupus erythematosus in patients in West Malaysia
J Clin Pathol
(1969) - et al.
Myelofibrosis as a cause of pancytopenia in systemic lupus erythematosus
J Clin Pathol
(1983) - et al.
Myelofibrosis as a cause of pancytopenia in systemic lupus erythematosus
J Clin Pathol
(1984)
Fibrosis of the bone marrow: content and causes
Br J Haematol
Hematologic abnormalities in AIDS
Am J Med
Megakaryoblastic leukemia (acute myelofibrosis): a report of three cases
Br J Haematol
Agnogenic myeloid metaplasia
Polycythemia vera: stem cell and probable clonal origin of the disease
N Engl J Med
Cited by (45)
Substance P and fibrotic diseases
2019, NeuropeptidesCitation Excerpt :At present, it is unclear whether fibrosis is secondary to immune dysfunction or vice versa. However, in patients with autoimmune diseases and myelofibrosis, treatment with immunosuppressive therapy resulted in the reversal of fibrosis (Kaelin and Spivak, 1986). SP, as a proinflammatory cytokine, has been demonstrated to play an important role in the pathophysiology of myelofibrosis.
Lessons learned from bone marrow failure in systemic lupus erythematosus: Case reports and review of the literature
2018, Seminars in Arthritis and RheumatismAutoimmune myelofibrosis: An update on morphologic features in 29 cases and review of the literature
2014, Human PathologyCitation Excerpt :Primary AIMF refers to AIMF cases in which patients have autoantibodies but do not have a well-characterized autoimmune disorder. Although isolated case reports have been published, it remains a poorly recognized disorder [1-24]. Various benign and malignant disorders can cause or be associated with a diffuse increase in bone marrow reticulin fibrosis.
Bone and joints in haematological malignancies (myeloma excluded)
2005, EMC-Rhumatologie-OrthopedieMimicry between neurokinin-1 and fibronectin may explain the transport and stability of increased substance P immunoreactivity in patients with bone marrow fibrosis
2001, BloodCitation Excerpt :Although the underlying cause of this subgroup is undefined, fibrosis could develop as a secondary process. The second is BM fibrosis, which occurs as a secondary process at various times after the initial diagnosis of polycythemia vera, essential thrombocythemia, chronic myeloid leukemia,2,8–10 myeloma,11lymphoma, and, infrequently, other nonhematologic disorders.12,13 The mechanism of BM fibrosis remains mostly undefined.
Myelofibrosis in systemic lupus erythematosus: A new case
2000, European Journal of Internal Medicine